Andere talen Seelos Therapeutics, Inc.

Aandelen

SEEL

US81577F2083

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,301 ^USD	-7,98%		-9,34%	-78,35%

19/03	Wall Street zal lager openen in aanloop naar tweedaagse Fed-vergadering; woningstartcijfers stijgen hoger dan verwacht	MT
19/03	ALS-behandeling van Seelos Therapeutics mislukt in tussentijds onderzoek	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03
Seelos Therapeutics' ALS treatment fails in mid-stage study	19/03
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	29/01
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	26/01
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	26/01
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration	23/01
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	22/01
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	22/01
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote 'FOR' All Proxy Proposals at the Special Meeting to be held on January 10, 2024	03/01
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024	02/01
Seelos Therapeutics, Inc. Releases Letter to its Stockholders	22/12
Sector Update: Health Care Stocks Gain Premarket Tuesday	19/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Seelos Therapeutics, Inc.

Aandelen

SEEL

US81577F2083

Andere talen

Filters